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BACKGROUND: The role of immune system in the pathogenesis and progression of breast cancer is a subject of controversy,
and this stimulated us to investigate the association of the immunophenotype of tumor-infiltrating lymphocytes in early breast
cancer with the spread of tumor cells to axillary lymph nodes.
METHODS: Tumor samples from 23 patients with early breast cancer from the Department of Gynecology and Obstetrics of
Ribeirão Preto Medical School (USP) were obtained at the time of biopsy and submitted to an enzyme-digestion procedure for the
extraction of tumor-infiltrating lymphocytes. The lymphocytes extracted were analyzed by dual-color flow cytometry with
monoclonal antibodies in these combinations: CD3 FITC/CD19 PE, CD3 FITC/CD4 PE, CD3 FITC/CD8 PE, and CD16/56
PerCP, which are specific for immunophenotyping of T and B lymphocytes, helper and cytotoxic T lymphocytes, and natural
killer (NK) cells. The mean percentage of these cells was used for comparing groups of patients with or without lymph node
metastasis.
RESULTS: The mean value for T-lymphocyte infiltration was 24.72 ± 17.37%; for B-lymphocyte infiltration, 4.22 ± 6.27%; for
NK-cell infiltration, 4.41 ± 5.22%, and for CD4+ and CD8+ T-lymphocyte infiltration, 12.43 ± 10.12% and 11.30 ± 15.09%,
respectively. Only mean values of T- and CD4+ T-lymphocyte infiltration were higher in the group of patients with lymph node
metastasis, while no differences were noted in the other lymphocyte subpopulations.
CONCLUSION: The association of tumor-infiltrating CD4+ T lymphocytes with lymph node metastasis suggests a role for these
cells in the spread of neoplasia to lymph nodes in patients with early breast cancer.
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INTRODUCTION
Breast cancer is the most common neoplasm in women,
and several studies have documented that these tumors are
infiltrated by a heterogeneous population of immune cells,
consisting of different proportions of T cells, B cells, natu-
ral killer (NK) cells, and macrophages.1–4 Despite the pres-
ence of the immune response, many breast tumors progres-
sively grow and spread, calling into question the role of
tumor-infiltrating leukocytes in the tumor micro-
environment.5
There is no definitive conclusion regarding the efficacy
of T cell-dependent immune mechanisms or regarding the
correlation between the extent and type of lymphocyte in-
filtration and the tumor progression in most subtypes of car-
cinoma of the breast.4,5 These interrelationships could be
considered to be important in view of the role played by
the immune system in the pathogenesis and progression of
the breast cancer.4
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Previous studies have shown that the function of tumor-
infiltrating lymphocytes is impaired by inhibitory
cytokines,6 increased regulatory T lymphocyte activity,7
tumor cell MHC molecule alterations,8 and aberrant Fas lig-
and expression,9 among others.
Nodal status as determined by pathologic examination
of lymph nodes has repeatedly been shown to be the sin-
gle most important predictor of survival in breast cancer.
Even patients with very small tumors and minimal involve-
ment of a single axillary node have a significantly worse
prognosis compared with patients with no axillary node in-
volvement; there is a direct relationship between the number
of involved axillary nodes and the risk for distant recur-
rence.10,11
Collectively, these findings have led to increased inter-
est in the role of tumor-infiltrating leukocytes in the regu-
lation of tumor development. In our study, we analyzed by
flow cytometry the tumor-infiltrating leukocytes of breast
cancer patients with T1 to T2 breast tumors in an attempt
to correlate phenotypical markers of tumor-infiltrating
leukocytes with axillary lymph node status.
PATIENTS AND METHODS
Patient population
During the years 2003 and 2004, a consecutive series
of 23 patients at the Department of Gynecology and Ob-
stetrics of the Ribeirão Preto Medical School who pre-
sented with invasive breast carcinoma were included in
the study for immunophenotyping the tumor-infiltrating
lymphocytes. In all patients, tumor size was no larger than
50 mm and was strictly confined to breasts, without dis-
tant metastasis; cases with involvement of skin, hypoder-
mis, or pectoral muscles or with deep fixation were ex-
cluded. All patients included in this study underwent cura-
tive surgery plus axillary lymph node dissection, and none
of these patients had received preoperative antitumor
therapy. The clinical and pathological characteristics of
patients included for the immunophenotypic studies are
summarized in Table 1.
Informed consent, approved by the Ethics Committee
of the Ribeirão Preto Medical School Hospital, was ob-
tained from patients for collecting the material in this study
(Process HCRP no 2519/2003).
Processing of tumor biopsy and preparation for flow
cytometry analysis
Samples of the primary tumor from the 23 patients were
obtained aseptically at the time of biopsy. The main bulk
of each tumor was sent for routine histology. A block of
tumor measuring 5 x 5 mm fresh from the operating room
was dissected away from necrotic and fatty tissue, minced
into 1 to 3-mm3 chunks using sterile forceps and a scalpel,
and placed in sterile RPMI 1640 (Sigma, Saint Louis, MO),
Table 1 - Clinical and pathological characteristics of patients with breast cancer
Case Age Tumor Grade Tumor Size(cm) TNM Stage Lymph node status1 Hormone status2
1 51 I 3.5 T2N0M0 IIA 3/25 Post
2 74 I 4.5 T2N0M0 IIA 0/19 Post
3 44 I 2.0 T1N2M0 IIIA 7/33 Pre
4 75 II 4.5 T2N1M0 IIB 0/16 Post
5 70 II 2.0 T1N0M0 I 0/18 Post
6 80 III 4.0 T2N1M0 IIB 13/22 Post
7 69 I 1.0 T1N0M0 I 0/18 Post
8 90 II 1.6 T1N0M0 I 0/21 Post
9 71 Mucinous 2.5 T2N0M0 IIA 0/15 Post
10 45 Mucinous 3.0 T2N0M0 IIA 3/12 Pre
11 59 II 2.5 T2N0M0 IIA 1/17 Post
12 64 I 1.8 T1N0M0 I 0/28 Post
13 53 I 3.0 T2N0M0 IIA 0/17 Post
14 40 I 3.0 T2N0M0 IIA 1/13 Pre
15 58 III 3.0 T2N2M0 IIIA 14/28 Post
16 51 II 4.0 T2N0M0 IIA 0/23 Pre
17 50 II 2.0 T1N0M0 I 12/27 Pre
18 48 II 2.0 T1N1M0 IIA 4/15 Post
19 42 I 1.0 T1N0M0 I 0/12 Pre
20 42 I 4.0 T2N0M0 IIA 0/12 Pre
21 63 II 2.0 T1N2M0 IIIA 8/25 Post
22 57 I 1.5 T1N0M0 I 0/9 Post
23 59 I 2.0 T1N0M0 I 0/21 Post
(1) Lymph node status: number of lymph nodes involved by metastasis/total number of lymph nodes
(2) pre: premenopausal; post: postmenopausal
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containing collagenase type IV (1 g/L; Sigma, Saint Louis,
MO), hyaluronidase type V (100 mg/mL; Sigma, Saint
Louis, MO), and DNAase type IV (30,000 U/L; Sigma,
Saint Louis, MO). Tumor digestion was performed for 40
minutes at 37o C in a sterile bottle. 10 mL of enzyme me-
dium was added per 3 g of tumor chunks. Following the
tumor digestion, the single-cell suspension was filtered
through a tissue dissociator grid, and the resultant suspen-
sion was washed twice and submitted to immunofluores-
cent staining of cells for flow cytometry. No attempt was
made to separate the tumor-infiltrating lymphocytes from
the tumor cells, since many cells would be lost, and this
might distort the proportions of the various mononuclear
cells present within the infiltrate.
Flow cytometry analysis of leukocyte infiltrate
The surface characteristics were determined by us-
ing the following preparations of monoclonal antibod-
ies: CD3 FITC/CD19 PE, CD3 FITC/CD4 PE, CD3
FITC/CD8 PE, and CD16/56 PerCP (Becton Dickinson,
Mountain View, CA), which allowed the lymphocytes be
phenotyped as T cells, B cells, CD4+ T cells, CD8+ T
cells, or NK cells, respectively. A 10 mL sample of a
phycoerythrin (PE)-, fluorescein-isothiocyanate (FITC)-
, or peridin-clorophyll-protein (PerCP)-conjugated anti-
body was added to 106 cells in 100 mL of phosphate-
buffered saline (PBS). After an incubation time of 30
min at 4o C in darkness, cells were washed twice and
resuspended in 500 mL PBS and then analyzed with a
FACSort flow cytometer (Becton Dickinson, San Jose,
CA). The cell samples were run through the flow cytom-
eter, and 10,000 events were analyzed for each sample
using Becton Dickinson’s CELL QUESTTM software on
an Apple Mac G3 computer.
Using the forward- and side-scatter (FSC and SSC)
properties of lymphocytes in laser light, a gate was drawn
around the lymphocytes to exclude tumor cells from fur-
ther analysis. The relative proportions of the phenotypic
subsets were measured using 4-quadrant analysis.
Statistical analysis
The data of each group were submitted to the normal-
ity test of GraphPad Prism (version 3.00) of GraphPad In-
corporated (San Diego, USA), and a gaussian distribution
of data was verified. Data were expressed as the mean ±
standard deviation, and the 2-tailed unpaired Student t test
was used for comparing leukocyte infiltration between
groups of patients with different lymph node status. Sta-
tistical significance was defined as P < 0.05.
RESULTS
All patients were treated by lumpectomy with axillary
lymph node dissection or modified radical mastectomy in
accordance with our management protocol. The patients
were women between 40 and 90 years of age (mean and
median were 58 years) and included 7 premenopausal and
16 postmenopausal women. According to the pathological
TNM classification of cancer staging, 11 of 23 tumors were
classified as T1, and 12 of 23 as T2. Lymph node metasta-
sis as determined by histological examination was noted
in 10 of 23 cases, with the remaining 13 patients being
lymph node negative.
Histologically, 21 of 23 patients had tumors classified
as infiltrating ductal carcinoma without special features,
while the remaining 2 were classified as mucinous. Tumors
with histology of ductal carcinoma were graded according
to the Bloom and Richardson grading system,12 and there
were a total of 11 ductal carcinomas classified as grade I,
8 as grade II, and 2 as grade III.
The mean value for T-lymphocyte infiltration (CD3+
cells) was 24.72 ± 17.37%; for B-lymphocyte infiltration
(CD19+ cells), 4.22 ± 6.27%; for NK cell-infiltration
(CD16+/CD56+ cells), 4.41 ± 5.22%; and for CD4+ and
CD8+ T-lymphocyte infiltration (CD3+/CD4+ and CD3+/
CD8+), 12.43 ± 10.12% and 11.30 ± 15.09%, respectively.
Comparing the two groups of patients—those with a
presence vs those with an absence of lymph node metasta-
sis—there was a statistically significant difference between
groups regarding the mean values of T-lymphocyte and
CD4+ T-lymphocyte infiltration (15.35 ± 2.36% and 8.41
± 6.22% with absence of lymph node metastasis vs 36.90
± 18.60% and 17.64 ± 12.05% with presence of lymph node
metastasis, P = 0.001 and P = 0.02, respectively) (Table
2), indicating an association between infiltration by CD4+
T cells and axillary metastasis. There were no statistically
significant differences between the means of other
lymphocyte subsets for these groups (Table 2).
Table 2 - Subpopulations of Immunocytes in Tumor Tissue
from Breast Carcinoma Specimens with Respect to Lymph
Node Involvementa,b
Subpopulations Positive lymph Negative lymph
node metastasis node metastasis
T lymphocyte 36.90 ± 18.60b.d 15.35 ± 8.51
B lymphocyte 6.77 ± 8.42b.c 2.51 ± 3.05
CD4+ T cell 17.64 ± 12.05b.e 8.41 ± 6.22
CD8+ T cell 17.89 ± 11.50b.c 13.25 ± 15.20
NK cell 4.70 ± 6.6 b.c 4.18 ± 4.10
a. All data are expressed as media percentages followed by standard
deviation; b. P < 0.05; c. P > 0.05; d. P = 0.001; e. P = 0.02
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DISCUSSION
In human breast cancer as well as in other solid tumors,
isolating tumor-infiltrating lymphocytes is difficult. In the
current study, we used dual-flow cytometry for accurate
detection of selected lymphocyte subsets, especially the
subpopulations of CD3+ tumor-infiltrating lymphocytes af-
ter enzyme-digestion method. In our study, the
immunophenotyping of cell types revealed a familiar sub-
division of lymphocytes. The tumor-infiltrating
lymphocytes, like peripheral blood lymphocytes, consisted
mainly of T cells expressing the CD3 antigen, and there
was a relative paucity of tumor-infiltrating B lymphocytes
and NK cells. The mechanisms by which T cells cause
tumor elimination include direct lysis of tumor, recruitment
of host cells that have a cytotoxic function, or secretion of
cytokines that are either cytotoxic toward tumor or affect
the tumor vasculature.14–18 Despite findings that the T-cell
immune response can kill tumors in situ, this response is
frequently ineffective in eliminating the tumor.14–18
There was little evidence of effectual action of tumor-
infiltrating B lymphocytes against cancer. Few proteins ex-
pressed by tumor cells are truly tumor-specific; most anti-
bodies produced will likely be directed against
autoantigens, with a small percentage against tumor-spe-
cific antigens.4–6,14 Another set of lymphocytes, NK cells,
seems to have tumoricidal activity that is not dependent
on prior sensitization. These are components of innate im-
munity, and pattern-recognition receptors and other cell-
surface molecules are used to directly detect tumors.15–17
Natural killer cells also monitor for the loss of MHC class
I molecules from the surface of the tumor cells, which com-
monly occurs during carcinogenesis.15,16,18 Most breast can-
cers display diminished MHC class I expression, making
them particularly vulnerable to NK cell-mediated killing.
However, our data showed that breast tumors are poorly
infiltrated by NK cells compared to T cells, and other stud-
ies have shown that the loss of MHC is associated with T-
cell infiltration instead of with NK-cell infiltration.15,18
Adaptive immunity is mediated by antibodies and by
CD4+ and CD8+ T cells, and it usually exploits an indirect
pathway, termed cross-priming, to achieve initial recogni-
tion of cancers.15–17 Accordingly, CD4+ and CD8+ T cells
react with MHC-restricted tumor peptides derived from
mutated proteins, aberrantly expressed gene products, and
normal differentiation antigens that are produced by the
cancer cells. Although specific immunity mediated by cy-
tolytic T lymphocytes might have an anticancer role, the
tumors escape from T-cell-based immune surveillance us-
ing various mechanisms, such as down regulation, muta-
tion, or loss of HLA class I molecules.3–6,15–18 In patients
with lymph node metastasis, an increased mean percent-
age of tumor-infiltrating CD4+ T cells, but not CD8+ T cells,
was seen. The relationship between tumor stage and T-
lymphocyte infiltration has previously been demonstrated
in patients with prostate, gallbladder, renal, colorectal, and
breast cancer.6,19–21
Nodal status as determined by pathologic examination
of lymph nodes has repeatedly been shown to be the sin-
gle most important predictor of survival in breast cancer.11,12
Association between the intensity of infiltration by T CD4+
lymphocytes and positive axillary lymph nodes has been
demonstrated, and these patients had a worse prognosis.3–
6,22,23
 Wong et al23 demonstrated that the tumor-infiltrating
lymphocytes of patients with positive lymph nodes had a
greater tumoricidal activity, but this may be reflect the need
for a more intense immune response in patients with tumor-
involved nodes or that in a significant subgroup of breast
cancer patients, tumor-infiltrating lymphocytes might cre-
ate a favorable environment for the spreading of malignant
cells.
Several findings of previous studies could explain this
association with worse prognosis. The tumor-infiltrating
lymphocytes are able to produce and release vascular en-
dothelial growth factor (VEGF) and basic fibroblastic
growth factor, which can induce lymphangiogenesis and
angiogenesis and consequently could permit the dissemi-
nation of cancer cells through lymphatics to regional lymph
nodes.24–28
Bernstein et al29 demonstrated that the aromatase
(CYP19) gene is presented in tumor-infiltrating
lymphocytes, and the presence of local oestrone formation
could have some functional significance for the estrogen-
dependent growth of breast cancer tissue, creating favorable
environment for cancer cells. The presence of tumor-infil-
trating lymphocytes in breast carcinomas and production
of potentially immunoinhibitory cytokines such as IL-4, IL-
10, and TGF-²1 has been demonstrated; this production by
tumor-infiltrating lymphocytes in breast cancers exceeded
that detected in benign breast lesions, suggesting a role for
tumor-infiltrating lymphocytes in immunosuppression, cre-
ating a mechanism of immune escape for the tumor.30
The matrix metalloproteinases are associated with the
invasive properties of tumor cells, owing to their ability to
degrade all major protein components of the extracellular
matrix and basement membranes, stimulate cell prolifera-
tion, and modulate angiogenesis,31 and it has been shown
that breast cancer cells can induce expression of matrix
metalloproteinase-9 (MMP-9) in fibroblasts by tumor cell-
derived TNF-α and TGF-β.31 The lymphocyte invasion of
a tumor mass is of crucial importance in the host’s defense
against the developing neoplasm, and has been shown that
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T lymphocytes constitutively produce small amounts of
MMP-9, a finding supported by the normal leukocyte mi-
gration from the vascular compartment to sites of inflam-
mation.33 However, Owen et al,34 evaluating the MMP-9
production by T cells from normal and mammary tumor-
bearing mice, have shown that mammary tumor cells pro-
duce MMP-9 and the T cells from tumor-bearing animals
constitutively produce higher levels of this enzyme and cor-
relate with tumor growth. These observations suggest that
tumor-infiltrating lymphocytes, regarded as evidence of a
protective immune response against tumors, can promote
angiogenesis and microvasculature remodeling. Thus, is
tempting to speculate that these factors may promote
neoplastic progression and dissemination throughout the
tumor site.
Our finding of an association of higher levels of tumor-
infiltrating CD4+ T lymphocytes with lymph node involve-
ment by metastasis may be explained by more recent stud-
ies showing that tumor-infiltrating lymphocytes are asso-
ciated with vasculogenesis, immunoinhibitory cytokines,
and intratumoral estrogen conversion. Although we recog-
nize that the findings to date are based on a limited number
of patients, our observations are supported by previous stud-
ies and could contribute importantly to the understanding
of mechanisms that govern the interactions between
lymphocytes and breast cancer.
RESUMO
Macchetti AH, Marana HRC, Silva JS, Andrade JM de,
Ribeiro-Silva A, Bighetti S. Linfócitos T CD4+ tumor
infiltrantes no câncer de mama inicial refletem
envolvimento linfonodal. Clinics. 2006;61(3):203-8.
INTRODUÇÃO: O papel do sistema imunológico na
patogênese e progressão do câncer de mama ainda é
controverso, e isto nos estimulou a verificar a associação
do imunofenótipo dos linfócitos tumor infiltrantes do
câncer de mama inicial com a disseminação de células
tumorais para os linfonodos axilares.
MÉTODOS: Amostras tumorais de 23 pacientes com
câncer de mama inicial do Departamento de Ginecologia
e Obstetrícia da Faculdade de Medicina de Ribeirão Preto
(USP) foram obtidas no momento da biópsia e depois
submetidas ao método de digestão enzimática para a
extração dos linfócitos tumor infiltrantes. Os linfócitos
extraídos foram analisados por citometria de fluxo com
anticorpos monoclonais nas seguintes combinações: CD3
FITC/CD19 PE, CD3 FITC/CD4 PE, CD3 FITC/CD8 PE,
e CD16/56 PerCP, específicos para imunofenotipagem de
linfócitos T e B, linfócitos T helper, linfócitos citotóxicos,
e células Natural Killer. Os valores médios destas
subpopulações leucocitárias foram comparados entre grupos
de pacientes com ou sem metástases linfonodais.
RESULTADOS: O valor médio do infiltrado por linfócitos
T foi 24,72±17,37%, para o infiltrado por linfócitos B foi
4,22±6,27%, e para o infiltrado por células Natural Killer foi
4,41±5,22%, e para o infiltrado por linfócitos T CD4+ e CD8+
foram, respectivamente, 12,43±10,12% e 11,30±15,09%. Os
valores médios do infiltrado por células T e T CD4+ foram
maiores no grupo de pacientes com metástase axilar, enquanto
nas outras subpopulações nada foi encontrado.
CONCLUSÃO: A associação dos linfócitos T CD4+ tumor
infiltrantes com metástases linfonodais sugere um papel
destas células na disseminação das células neoplásicas aos
linfonodos dos pacientes com câncer de mama inicial.
UNITERMOS: Câncer de Mama. Citometria de Fluxo.
Linfócitos. Células Natural Killer.
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